

# Dermatologic Disease in IBD: What the Gastroenterologist Needs to Know

Alan Menter, MD

Baylor Scott & White, Dallas, TX

IBD Symposium  
14, April 2018

# Dermatologic Diseases in IBD

- Erythema Nodosum
  - Most common
  - Up to 15% of patients
- Pyoderma Gangrenosum (up to 3%)
- Psoriasis
- Hidradenitis Suppurative resembling (Crohn's disease-17% incidence)
- Leucocytoclastic Vasculitis

# Erythema Nodosum



# Common Conditions Associated with Erythema Nodosum (1)

- Streptococcus B haemolyticus infection
- Primary Tuberculosis
- Yersinia, salmonella, coccidioidomycosis, and heliobacter infections

## **Systemic Disease**

- Sarcoidosis
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Behcet's disease
- Connective tissue disease
- Sweet's syndrome

### **Malignancy**

- Haematological neoplasms (lymphoma)

### **Drugs**

- Oral contraceptives
- Penicillins
- Sulfonamides
- Bromides
- Iodides
- Analgesics

### **Pregnancy**

# Pyoderma Gangrenosum



# Differential Diagnosis of Pyoderma Gangrenosum (1)

- Bacterial infection
- Mycobacterial infection
- Fungal infection
- Parasitic infection
- Viral infection

# Differential Diagnosis of Pyoderma Gangrenosum (2)

- Sweet's syndrome
- Spider bite
  - Brown recluse spider
- Malignancy
  - Squamous cell carcinoma
  - Basal cell carcinoma
  - Cutaneous T cell lymphoma

# Differential Diagnosis of Pyoderma Gangrenosum (3)

- Factitial ulceration
- Vascular disease
- Antiphospholipid antibody associated occlusive disease
- Thrombophlebitis with gangrene
- Systemic disease
  - Sytemic lupus erythematosus
  - Rheumatoid arthritis
  - Behcet's disease
  - Wegener's granulomatosis

# Orofacial Manifestations in IBD

Aplthous Up to 20% incidence

- Stomatitis
- Pyostomatitis Vegetans
- Angular Cheilitis (Candidiasis-common)
- Cobblestoning of the buccal mucosa
- Nodules on the gingival and alveolar mucosa

## Secondary Cutaneous Manifestations due to complications of IBD or its Therapies

- Acquired Acrodermatitis Enteropathica
- Pellagra (Niacin deficiency)
- Scurvy (Vitamin C deficiency)
- Purpura (Vitamin C & K)
- Hair & Nail Abnormalities (malabsorption of amino acids)
- Nodules on the gingival and alveolar mucosa

# IBD and Psoriasis

- The most frequently associated cutaneous disease is psoriasis which occurs in 7-11% of the IBD population compared to the 2% of general population.
- In one study, psoriasis was found to be more prevalent in Crohn's (11.2%) than Ulcerative Colitis (5.7%)
- The association of IBD with psoriasis is believed to be both genetically and immunologically related
- In a recent study of 146 patients with both IBD and psoriasis compared to a control of 146 patients with only psoriasis, it was found that patients with both IBD and psoriasis had significantly
  - higher rates of autoimmune thyroiditis (6.8 vs 2.1%)
  - hepatitis (6.2 vs 0.7%),
  - diabetes (26.7 vs 11.0%)



# PATIENTS WITH PSORIASIS HAVE HIGHER RATES OF IBD

**~3.5x INCREASED PREVALENCE**

of IBD in US patients with psoriasis (n=5492) vs matched controls (n=5492)<sup>1</sup>

**~4x INCREASED RISK**

of CD in US women (N=174,476) with confirmed psoriasis, according to 2 studies<sup>2</sup>



## GENETICS<sup>3</sup>

- Psoriasis and IBD may be genetically linked




## DISEASE COURSE<sup>4</sup>

- The onset of psoriasis usually precedes IBD
- The course of psoriasis is independent of IBD disease activity



# PLAQUE PSORIASIS AND HS LOOK DIFFERENT ON THE SURFACE

## Plaque Psoriasis<sup>2</sup>



**Common  
Locations<sup>1</sup>**

- Raised, reddish patches
- Silvery-white scales
- Itch
- Nail problems

## HS<sup>3,4</sup>



**Common  
Locations<sup>3</sup>**

- Painful nodules or abscesses
- Double open comedones
- Draining sinus tracts
- Bridged scarring



# DIAGNOSING PLAQUE PSORIASIS AND HS

## BOTH RELY ON A PHYSICAL EXAM<sup>1,2</sup>

### Plaque psoriasis:

Examination of skin, nails, and scalp for symptoms<sup>3-5</sup>



**HS:** Examination of common locations for nodules, abscesses, sinus tracts, and scars<sup>2,6-8</sup>



1. NPF. [https://www.psoriasis.org/sites/default/files/diagnosing\\_psoriasis\\_fact\\_sheet.pdf](https://www.psoriasis.org/sites/default/files/diagnosing_psoriasis_fact_sheet.pdf). Accessed August 22, 2017. 2. Micheletti RG, *Semin Cutan Med Surg*. 2014;33(3 Suppl):S51-53. 3. Baliwag J, et al. *Cytokine*. 2015;73(2):342-350. 4. Weigle N, McBane S. *Am Fam Physician*. 2013;87(9):626-633. 5. Wozel G, *Clin Dermatol*. 2008;26(5):448-459. 6. Revuz J, *J Eur Acad Dermatol Venereol*. 2009;23(9):985-998. 7. Ingram JR, UpToDate. <https://www.uptodate.com/contents/hidradenitis-suppurativa-acne-inversa-pathogenesis-clinical-features-and-diagnosis>. Accessed August 22, 2017. 8. Gill L, et al. *F1000Prime Rep*. 2014;6:112.



# DIFFERENT PRESENTATION, BUT SEVERAL SHARED COMORBIDITIES

The list of comorbidities associated with psoriasis and HS is extensive, and there are several that are similar between these 2 conditions

## Comorbidities of Plaque Psoriasis<sup>1</sup>

- Psoriatic arthritis
- Cardiovascular disease
- Metabolic syndrome
- Depression
- Crohn's disease (CD)
- Ulcerative colitis (UC)

## Comorbidities of HS<sup>2-6</sup>

- Spondyloarthritis\*
- Cardiovascular disease
- Metabolic syndrome
- Depression
- Crohn's disease (CD)
- Ulcerative colitis (UC)

\*Includes ankylosing spondylitis and psoriatic arthritis.

1. Menter A, et al. *J Am Acad Dermatol.* 2008;58(5):826-850. 2. Richette P, et al. *J Rheumatol.* 2014;41(3):490-494. 3. Arthritis Foundation. <http://www.arthritis.org/about-arthritis/types/spondyloarthritis/>. Accessed August 21, 2017. 4. Egeberg A, et al. *JAMA Dermatol.* 2016;152(4):429-434. 5. Miller IM, et al. *JAMA Dermatol.* 2014;150(12):1273-1280. 6. Miller IM, et al. *Dermatol Clin.* 2016;34(1):7-16.



# CONSEQUENCES OF HS PROGRESSION<sup>1</sup>


- Lymphatic obstruction
- Squamous cell carcinoma
- Anemia
- Malaise
- Arthropathy
- Infections
- Contractures and limb mobility limitation

## Complications can affect the skin alone or may have broader impact<sup>2</sup>

As HS progresses, small lesions can develop into deep-seated nodules and abscesses and rupture, leading to scars that can thicken over time and impair movement<sup>3-5</sup>



Patient with a small nodule in the armpit<sup>6</sup>



Patient with scarring and fistulae in the armpit<sup>6</sup>

1. Margesson LJ, Danby FW. *Best Pract Res Clin Obstet Gynaecol.* 2014;28(7):1013-1027. 2. Yuan JT, Naik HB. *Semin Cutan Med Surg.* 2017;36(2):79-85. 3. AAD. <https://www.aad.org/public/diseases/painful-skin-joints/hidradenitis-suppurativa>. Accessed August 21, 2017. 4. Ingram JR. UpToDate. <https://www.uptodate.com/contents/hidradenitis-suppurativa-acne-inversa-pathogenesis-clinical-features-and-diagnosis> Accessed August 22, 2017. 5. Alikhan A, et al. *J Am Acad Dermatol.* 2009;60(4):539-561. 6. No BS About HS. <https://www.nobsabouths.com/what-is-hidradenitis-suppurativa/symptoms>. Accessed August 21, 2017.


# CUTANEOUS MANIFESTATIONS OF CD MAY BE DIFFICULT TO DIFFERENTIATE FROM HS<sup>1</sup>

What Is the Diagnosis?



Perianal/Vulvar Cutaneous Manifestations of CD

Perianal/Vulvar HS




Comparing Select Features





# MRI DISTINCTION OF PERIANAL HS FROM CD<sup>1\*</sup>

Fistulae also communicate more often with the anal sphincters in patients with CD than those with HS



## MR image of patient with CD:

Fistula communicates with the sphincter mechanism, involving the perianal area and ischioanal fossa



## MR image of patient with HS:

Fistula does not extend to the sphincter complex

## MRI signs of HS-related perianal disease include

- Bilaterality of abnormalities
- Absence of rectal wall thickening
- Either posterior localization of lesions or absence of predominance of lesions in the perianal area

\*Retrospective French study of adults with HS (n=23) and CD (n=46) that underwent pelvic MRI for suspicion or evaluation of anoperineal disease.

MRI=magnetic resonance imaging.

1. Monnier L, et al. *Eur Radiol.* 2017;27(10):4100-4109.



# HS IN OTHER COMMON LOCATIONS



Inframammary<sup>1</sup>



Axilla<sup>2</sup>



Buttocks<sup>3</sup>




# IBD MAY AFFECT MORE THAN JUST THE GUT

In a large cohort study, extraintestinal manifestations (EIMs) were identified in<sup>1</sup>

**43%**  
(n=580)  
of patients  
with CD

**31%**  
(n=370)  
of patients  
with UC



**Multiple organ systems can be affected by IBD<sup>1,2</sup>**

- Skin
- Joints
- Eyes
- Liver

**Musculoskeletal manifestations<sup>2</sup>**

- Ankylosing spondylitis
- Psoriatic arthritis


**Cutaneous manifestations or associations<sup>1</sup>**

- Perianal lesions
- Erythema nodosum
- Pyoderma gangrenosum
- Psoriasis



# EXTRAINTESTINAL MANIFESTATIONS (EIMs) MAY OCCUR BEFORE OR AFTER AN IBD DIAGNOSIS<sup>1</sup>

## Chronology of EIM Occurrences<sup>1,2</sup>



**IN YOUR PATIENTS WITH PSORIATIC DISEASE,  
BE AWARE OF THE POTENTIAL FOR IBD**


# IMMUNE DYSREGULATION: A SHARED CONNECTION

## Plaque Psoriasis<sup>1-3</sup>

Proinflammatory cytokines contribute to cyclic inflammation and keratinocyte proliferation

## IBD<sup>6</sup>

Proinflammatory cytokines contribute to the development and potential perpetuation of mucosal inflammation



## HS<sup>4,5</sup>

The production of proinflammatory cytokines initiates the pathogenic process

The inflammatory response in immune-mediated diseases is highly complex. This example does not reflect a complete list of cytokines involved. Select cytokines have been highlighted based on their involvement in the pathogenesis of multiple disease states.

IFN=interferon. IL=interleukin. TNF=tumor necrosis factor.

1. Nickoloff BJ. *Nat Med*. 2007;13(3):242-244. 2. Nestle FO, et al. *N Engl J Med*. 2009;361(5):496-509. 3. Lowes MA, et al. *Annu Rev Immunol*. 2014;32:227-255. 4. van der Zee HH, et al. *Exp Dermatol*. 2012;21(10):735-739.

5. van der Zee HH, et al. *Br J Dermatol*. 2011;164(6):1292-1298. 6. Neurath MF. *Nat Rev Immunol*. 2014;14(5):329-342.

# Pathology: Hidradenitis Suppurative

- Active
- Primary lesions:
  - Acute form: recurrent, painful, deep-seated, inflamed nodules
  - Symptoms: burning, itch, pain, local warmth, hyperhidrosis
- Abscesses form sinus tracts that re-epithelize and contain inflammatory material
  - May drain to skin surface
  - Multiple tracts may coalesce to form subcutaneous honeycomb



# Hidradenitis Suppurative Clinical presentation: Chronic form

- Multiple abscesses
- Double comedones
- Foul-smelling discharge
- Secondary lesions
  - Scarring
  - Ulceration
  - Sinus tracts
- May be more than one phenotype (comedonal versus other)



# Hidradenitis Suppurative Hurley staging system



**Stage I**  
Single or multiple  
abscesses

**Stage II**  
Recurrent abscesses,  
sinus tract formation

**Stage III**  
Diffuse involvement  
of area, multiple  
interconnected tracts  
and abscesses

# Hidradenitis Suppurative



# Hidradenitis Suppurative Microbiology

- HS is a sterile inflammation
  - Aerobic: Staphylococcus – coag neg
  - Anaerobic: Peptostreptococcus
  - Corynebacterium
  - No substantial role for staph aureus
- Immune-mediated mechanisms of inflammation
  - Dysregulated immune response in the hair follicles
  - Antibiotics for antimicrobial but also anti-inflammatory effects
- Biofilm and microbiome may be relevant

# Hidradenitis Suppurative Risk factors


## ■ Smoking

- Increases severity
- HS vs matched controls:  
odds ratio = 12.55

## ■ Obesity

- Correlation with severity
- HS vs matched controls:  
odds ratio = 4.42

## • Johns Hopkins Questionnaire



- Role of smoking and obesity not known to be causal, but high incidence suggests that modifying these factors is reasonable as an adjuvant therapy.

# Complications of Hidradenitis Suppurative

- Scars
- Restricted movement
- Obstructed lymph drainage
- Psychosocial issues



# Depression in Patients with Hidradenitis Suppurative

- 211 HS patients and 233 dermatological control patients
- DLQI was significantly higher for HS patients than for the control patients,  $8.4 \pm 7.5$  vs.  $4.3 \pm 5.6$  ( $P < 0.0001$ ) correlated with Hurley stage severity scores
- Mean MDI scores were significantly higher for HS patients, 11.0 vs. 7.2 ( $P < 0.0001$ )
- Clinically defined depression rates (ICD-10) criteria were not significantly higher in HS patients compared with controls (9% vs. 6%)

# Hidradenitis Suppurative Sexual health

- Questionnaire given to 45 women (24 HS, 21 control) and 40 men (20 HS, 20 control). DLQI used for QoL. The Female Sexual Function Index, the International Index of Erectile Dysfunction, and the Frankfurt Self-Concept Scale for Sexuality were used to assess sexual health
- HS subjects exhibited sexual distress compared with control group ( $P < 0.01$ )
- Distress was higher in female patients with HS ( $P = 0.02$  compared with male HS patients)
- Greater sexual dysfunction and distress correlated with lower QoL in female patients with HS

DLQI, dermatology life quality index ; HS, hidradenitis suppurativa; QoL, quality of life.

# TABLE Diseases Commonly Associated With Hidradenitis Suppurativa

## Diseases of follicular occlusion (follicular occlusion triad)

- Acne Vulgaris
- Acne conglobata
- Dissecting cellulitis of the scalp

Pilonidal cyst

Crohn's disease

Obesity/metabolic syndrome

# Hidradenitis Suppurativa: Update on Diagnosis and Treatment



## Introduction

Hidradenitis Suppurativa: Current Views on Epidemiology, Pathogenesis, and Pathophysiology

Natural History, Presentation, and Diagnosis of Hidradenitis Suppurativa

Recognizing and Managing Comorbidities and Complications in Hidradenitis Suppurativa

Current and Emerging Nonsurgical Treatment Options for Hidradenitis Suppurativa

What You Should Know About Hidradenitis Suppurativa: Information for Patients

Post-Test and Evaluation Form

**Original Release Date:** June 2014

**Most Recent Review Date:** June 2014

**Expiration Date:** July 31, 2016

**Estimated Time to Complete Activity:** 3.0 hours

**Medium or Combination of Media Used:** Written Supplement

**Method of Physician Participation:** Journal Supplement

## Faculty

**Francisco A. Kerdel, BSc, MBBS**

Director of Inpatient Dermatology  
University of Miami Hospital  
Professor of Dermatology and Vice Chairman  
Florida International University  
Miami, Florida

**Alan Menter, MD**

Chief, Division of Dermatology  
Baylor University Medical Center  
Clinical Professor of Dermatology  
University of Texas, Southwestern Medical School  
Director, Fellowship Program  
Baylor Psoriasis Center  
Chair, Psoriasis Guidelines Committee,  
American Academy of Dermatology  
Dallas, Texas

**Robert G. Micheletti, MD**

Assistant Professor of Dermatology and Medicine  
Perelman School of Medicine at the University  
of Pennsylvania  
Philadelphia, Pennsylvania

**Reprinted from  
Seminars in Cutaneous  
Medicine and Surgery**

The manuscript was originally published as a supplement to *Seminars in Cutaneous Medicine and Surgery*, Vol. 33, No. 3S, June 2014. It has been reviewed and approved by the faculty as well as the Editors of *Seminars in Cutaneous Medicine and Surgery*.

The Guest Editors acknowledge the editorial assistance of Global Academy for Medical Education, LLC, and Joanne Still, medical writer, in the development of this supplement.

This continuing medical education (CME) supplement was developed from interviews with the faculty. Neither the editors of *Skin & Allergy News* nor the Editorial Advisory Board nor the reporting staff contributed to its content. The opinions expressed are those of the faculty and do not necessarily reflect the views of the supporter or of the Publisher.

Copyright © 2014 by Global Academy for Medical Education, LLC, Denville Medical Communications Inc. and its Licensees. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher: Global Academy for Medical Education, LLC. We do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.



**Global Academy for  
Medical Education**

## Hidradenitis Suppurativa: Update on Diagnosis and Treatment

- 4 Introduction**  
Francisco A. Kerdel, BSc, MBBS, Alan Menter, MD,  
and Robert G. Micheletti, MD
- 5 Hidradenitis Suppurativa: Current Views on  
Epidemiology, Pathogenesis, and Pathophysiology**  
Robert G. Micheletti, MD
- 8 Natural History, Presentation, and Diagnosis of  
Hidradenitis Suppurativa**  
Robert G. Micheletti, MD
- 11 Recognizing and Managing Comorbidities and  
Complications in Hidradenitis Suppurativa**  
Alan Menter, MD
- 14 Current and Emerging Nonsurgical Treatment Options  
for Hidradenitis Suppurativa**  
Francisco A. Kerdel, BSc, MBBS
- 17 What You Should Know About Hidradenitis  
Suppurativa: Information for Patients**
- 19 Post-Test**
- 20 Evaluation Form**

### Faculty



**Francisco A. Kerdel, BSc, MBBS**  
Director of Inpatient Dermatology  
University of Miami Hospital  
Professor of Dermatology and Vice Chairman  
Florida International University  
Miami, Florida



**Alan Menter, MD**  
Chief, Division of Dermatology  
Baylor University Medical Center  
Clinical Professor of Dermatology  
University of Texas, Southwestern Medical School  
Director, Fellowship Program  
Baylor Psoriasis Center  
Chair, Psoriasis Guidelines Committee  
American Academy of Dermatology  
Dallas, Texas



**Robert G. Micheletti, MD**  
Assistant Professor of Dermatology and Medicine  
Perelman School of Medicine at the University of Pennsylvania  
Philadelphia, Pennsylvania

# Dermatologic Disease in IBD: What the Gastroenterologist Needs to Know

Alan Menter, MD

Baylor Scott & White, Dallas, TX

IBD Symposium  
14, April 2018